Aerie Pharmaceuticals Incの資本の返還
Aerie Pharmaceuticals Incの資本の返還は何ですか。
Aerie Pharmaceuticals Incの資本の返還は32.63%です。
資本の返還の定義は何ですか。
株主資本利益率は、株主資本の簿価との関係で事業の収益性の尺度です。これは、会計年度純利益を株主資本合計で除算することによって計算されます。
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
NASDAQのセクタHealth Careにおける資本の返還の企業と比べるAerie Pharmaceuticals Inc
Aerie Pharmaceuticals Incは何をしますか。
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Aerie Pharmaceuticals Incと類似の資本の返還
- Accenture plcの資本の返還は32.59%です。
- Denburyの資本の返還は32.60%です。
- Synalloyの資本の返還は32.61%です。
- Check Point Software Technologiesの資本の返還は32.61%です。
- China Ceramics Coの資本の返還は32.61%です。
- Southern Copperの資本の返還は32.62%です。
- Aerie Pharmaceuticals Incの資本の返還は32.63%です。
- 1137943の資本の返還は32.64%です。
- Arena REITの資本の返還は32.65%です。
- Emcorの資本の返還は32.67%です。
- Pzena Investment Management Incの資本の返還は32.68%です。
- Établissements Maurel & Prom SAの資本の返還は32.71%です。
- Altisource Portfolio Solutions S.Aの資本の返還は32.72%です。